ArriVent BioPharma, Inc.
AVBPDrugs in Pipeline
2
Phase 3 Programs
2
Upcoming Catalysts
1
Next Catalyst
Aug 10, 2026
6dMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
AVBP Earnings Report
EPS Est: $-0.98 | FQ end 2026-06
furmonertinib 240 mg oral, daily
Metastatic Non-Small Cell Lung Cancer
Firmonertinib
Non-Small-Cell Lung Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
furmonertinib 240 mg oral, daily | Phase 3 | Metastatic Non-Small Cell Lung Cancer | - | - |
Firmonertinib | Phase 3 | Non-Small-Cell Lung Cancer | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in ArriVent BioPharma, Inc.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in ArriVent BioPharma, Inc.'s (AVBP) pipeline across Phase 3. Its lead program is furmonertinib 240 mg oral, daily (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is ArriVent BioPharma, Inc.'s next FDA catalyst?→
ArriVent BioPharma, Inc.'s (AVBP) next tracked catalyst is a Earnings expected August 10, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track AVBP biotech catalysts?→
Add AVBP to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow ArriVent BioPharma, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.